Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, PK, and preliminary pharmacodynamics of QBW251 in healthy subjects and cystic fibrosis patients; study terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• QBW251

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-07-19